Thought needs to be given to how to blunt the impact of the rare pediatric disease priority review voucher program on FDA's drug review operations, pharma company and patient advocacy group representatives suggested at the recent World Orphan Drug Congress USA in Washington, DC.
During a panel discussion on legislation to renew the voucher program, it was clear that industry and rare disease advocates...